Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment

The American Journal of Medicine
P D MillerC H Chesnut

Abstract

To determine the efficacy and safety of cyclical etidronate for up to 7 years in the treatment of postmenopausal osteoporosis and to examine the effects of discontinuing treatment after 2 or 5 years of therapy. Patients were randomized at entry into the original study in 1986 to blinded treatment for 2 years with either a calcium (placebo) or an intermittent cyclical etidronate regimen, which most patients continued for a third year. Following this phase of the study, patients were enrolled into an open-label, follow-up study (years 4 and 5), during which all patients received cyclical etidronate treatment. In the present double-blind study (years 6 and 7), patients were rerandomized to receive intermittent cyclical therapy with either etidronate or placebo; all patients received calcium. The treatment regimen consisted of 400 mg/day etidronate or placebo for 14 days, followed by 76 days of elemental calcium (500 mg/day); this cycle was repeated approximately 4 times in each year. Of the 193 patients who continued in years 6 and 7 of the study, 93 were randomized to receive cyclical etidronate and 100 were randomized to receive calcium only. For purposes of efficacy analyses, patients were categorized by their total years of cu...Continue Reading

References

Jan 1, 1991·Calcified Tissue International·C Christiansen
Jul 12, 1990·The New England Journal of Medicine·N B WattsM J Yanover
Nov 1, 1994·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·E G LufkinB L Riggs
Apr 1, 1994·British Journal of Rheumatology·H Mulder, A Struys
May 1, 1993·The Journal of Clinical Investigation·M SahniT J Martin
Oct 3, 1996·The New England Journal of Medicine·P C de GroenK K Wang

❮ Previous
Next ❯

Citations

Nov 24, 1998·Aging : Clinical and Experimental Research·C Gennari, J Y Reginster
Jun 28, 2002·The New England Journal of Medicine·Elizabeth R Jenny-Avital
Aug 9, 2003·Expert Opinion on Drug Safety·John K Marshall
Aug 9, 2003·Expert Opinion on Drug Safety·Ian R Reid
Mar 16, 2001·Expert Opinion on Pharmacotherapy·M R McClung
Dec 4, 2003·Expert Opinion on Pharmacotherapy·Paul D Miller
May 31, 2006·Expert Opinion on Pharmacotherapy·Marc C Hochberg, René Rizzoli
Aug 22, 2007·The American Journal of Chinese Medicine·Min WeiWing Cho Sse
Aug 15, 2003·Clinics in Geriatric Medicine·Nelson B Watts
Jan 25, 2005·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Katsuyuki YamaguchiTakeshi Fuji
Jun 30, 2001·Seminars in Nuclear Medicine·G M Blake, I Fogelman
Jun 29, 2011·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Dawn C MackeySteven R Cummings
Jul 7, 1999·Journal of Clinical Pharmacology·D L Brown, R Robbins
Jul 3, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Kristine E EnsrudUNKNOWN Fracture Intervention Trial Long-Term Extension Research Group
Mar 11, 2006·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Nguyen D NguyenTuan V Nguyen
Feb 19, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·P D DelmasCyrus Cooper
Jan 10, 2019·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·S Nayak, S L Greenspan
Oct 13, 2006·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Richard J WenstrupThomas N Hangartner
Oct 18, 2006·Reviews in Endocrine & Metabolic Disorders·Sumapa Chaiamnuay, Kenneth G Saag
Jan 26, 2007·Der Orthopäde·S ReinsdorfA A Kurth
Jul 23, 2005·Current Osteoporosis Reports·Julian M R MathooJonathan D Adachi
May 8, 2008·Journal of Medical Virology·Yasuji AraseHiromitsu Kumada
Apr 24, 2008·Current Osteoporosis Reports·Adriana Ioachimescu, Angelo Licata
Sep 12, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Raheem B KheraniJonathan D Adachi
Oct 6, 1999·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·R G RussellH A Fleisch
Dec 29, 2000·Obstetrical & Gynecological Survey·N B Watts
Feb 7, 2008·The Cochrane Database of Systematic Reviews·G A WellsP Tugwell
Jan 14, 2000·The Journal of Clinical Endocrinology and Metabolism·R D Wasnich, P D Miller
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Pfeilschifter, I J Diel
Sep 30, 2004·Calcified Tissue International·D D MellströmA A Chines
Mar 12, 2005·Current Rheumatology Reports·Ira Pande, David J Hosking
Jul 9, 1999·Hospital Medicine·N W Liggett, D M Reid
Jul 23, 2005·Current Osteoporosis Reports·Ira Pande, David J Hosking
Aug 6, 1999·Obstetrical & Gynecological Survey·N B Watts
Oct 29, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P VergneR Trèves
Jan 13, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Stephen F HodgsonUNKNOWN AACE Osteoporosis Task Force

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.